Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission

NCT05116228 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped Failure to recruit

Conditions

Rheumatoid Arthritis
Remission

Interventions

DRUG: 500mg RTX Group
DRUG: 1000mg RTX Group

Sponsor

Medical University of Vienna